American Century Companies Inc. Raises Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

American Century Companies Inc. increased its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 11.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 428,940 shares of the company's stock after acquiring an additional 42,526 shares during the quarter. American Century Companies Inc. owned about 0.68% of Vera Therapeutics worth $18,140,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of VERA. Holocene Advisors LP lifted its holdings in shares of Vera Therapeutics by 8.8% in the 3rd quarter. Holocene Advisors LP now owns 1,954,528 shares of the company's stock valued at $86,390,000 after purchasing an additional 158,451 shares during the last quarter. Geode Capital Management LLC increased its position in Vera Therapeutics by 2.1% during the third quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company's stock worth $44,415,000 after buying an additional 20,223 shares during the period. Jennison Associates LLC lifted its stake in Vera Therapeutics by 82.0% in the fourth quarter. Jennison Associates LLC now owns 813,861 shares of the company's stock valued at $34,418,000 after buying an additional 366,763 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Vera Therapeutics by 19.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 430,665 shares of the company's stock valued at $18,213,000 after acquiring an additional 68,860 shares during the period. Finally, Lord Abbett & CO. LLC grew its position in shares of Vera Therapeutics by 41.1% during the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company's stock worth $18,830,000 after acquiring an additional 124,197 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.

Remove Ads

Insider Activity

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the business's stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total transaction of $730,450.00. Following the sale, the chief executive officer now directly owns 143,603 shares in the company, valued at approximately $5,993,989.22. The trade was a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 21.70% of the company's stock.

Vera Therapeutics Stock Performance

VERA traded down $1.43 during trading on Friday, reaching $21.31. The company's stock had a trading volume of 1,278,591 shares, compared to its average volume of 771,536. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The company's fifty day moving average price is $29.82 and its 200-day moving average price is $38.34. Vera Therapeutics, Inc. has a 52-week low of $20.27 and a 52-week high of $51.61. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -8.16 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11. On average, equities analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analyst Ratings Changes

VERA has been the subject of several research reports. Guggenheim upped their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. JPMorgan Chase & Co. reduced their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. Wolfe Research began coverage on Vera Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target on the stock. Finally, The Goldman Sachs Group began coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 price objective for the company. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Vera Therapeutics has a consensus rating of "Buy" and an average target price of $64.67.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.